Brind.
  1. Drug approvals are pending from the FDA, while GSK seeks to challenge competitor lung cancer treatments, adding near-approval therapies to its portfolio.
  2. GSK gained FDA clearance for a lung cancer medicine, while the FDA began reviewing other highly anticipated drugs.

GSK is seeking priority review for its Jemperli application, and the FDA set the PDUFA action date.

2 reports, 1 independent Updated Aug 28
Gone quiet
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

GSK is seeking priority review for its Jemperli application, and the FDA set the PDUFA action date.

Who's involved

What this event is mainly about
GSKFDA

Keep exploring

Part of

GSK gained FDA clearance for a lung cancer medicine, while the FDA began reviewing other highly anticipated drugs. All 1 developments

Within Drug approvals are pending from the FDA, while GSK seeks to challenge competitor lung cancer treatments, adding near-approval therapies to its portfolio.

The entities involved

Related events

Coverage

Newest first; wire copies grouped
1 more outlet ran the same wire story